Abbott (ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation, PFA, therapy with the Volt PFA System for the treatment of atrial fibrillation. The data also highlights the excellent safety profile of the Volt PFA System alongside the system’s ability to achieve results with fewer therapy applications than on-market competitive PFA systems. PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac tissue causing abnormal heart rhythms. Abbott designed its Volt CE Mark Study to assess the impact of the Volt PFA System in two different patient groups – people battling paroxysmal atrial fibrillation – episodes that come and go – as well as persistent AFib – episodes that last longer than seven days.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- China weighing exemption of some U.S. goods from tariffs, Bloomberg reports
- Medtronic submits application to FDA for interoperable insulin pump
- Top 3 Trending Stocks, According to Analysts – 4/18/2025
- Abbott Laboratories’ Earnings Call Highlights Robust Growth
- Abbott price target raised to $145 from $140 at RBC Capital